Description
Packing
Per pack 50 pcs.
Pharmacological action
Ursoliv has hepatoprotective, choleretic, cholelipideolipidelioma cholelomeolipidelioma cholelomeolipidelioma cholelomeolipidelioma.
In vitro studies have shown that ursodeoxycholic acid (UDCA) has a direct protective effect on liver cells and reduces the hepatotoxicity of hydrophobic bile salts.
The main effects of UDCA on cholesterol metabolism include: lowering cholesterol secretion, decreasing its intestinal absorption and stimulating cholesterol from cholesterol stones to bile. UDCA, inhibiting GMK-CoA reductase, also has a moderate inhibitory effect on the synthesis of cholesterol in the liver, increases the solubility of cholesterol in the biliary system. It causes partial or complete dissolution of cholesterol gallstones during enteral use, reduces the saturation of bile with cholesterol,
stimulates the formation and secretion of bile, accelerates the elimination of toxic bile acids through the intestines.
When taken orally, the proportion of UDCA in the total pool of bile acids increases significantly. UDCA competes with other bile acids during absorption in the small intestine, as well as with penetration of hepatocyte through the membrane, which leads to a decrease in the absorption of toxic bile acids in the intestine and their entry into the liver, preventing their cytopathogenic effect. Reduces the lithogenicity of bile, increases the concentration of bile acids in it, causes increased gastric and pancreatic secretion, enhances lipase activity, has a hypoglycemic effect.
It has an effect on immunological reactions, decreasing the pathological expression of antigens of the main histocompatibility complex HLA I on hepatocytes and HLA II on cholangiocytes, inhibits the production of interleukin 2, reduces the number of eosinophils
Indications
– Primary biliary cirrhosis with no signs of decompensation (symptomatic therapy)
– Dissolution of small and medium cholesterol stones with functioning gall bladder
– Biliary reflux gastritis.
Contraindications
– The size of cholesterol stones in the gallbladder is more than 20 mm. The presence of radiopaque (high calcium) gallbladder stones and the common bile duct.
– Atrophy of the gallbladder in gallstone disease, non-functioning gallbladder. Obstruction of the biliary tract. Acute inflammatory diseases of the gallbladder, bile ducts and intestines.
– Cirrhosis of the liver in the stage of decompensation.
– Severe hepatic and renal failure.
– Pancreatitis (active phase).
– Hypersensitivity to the drug.
– Pregnancy, lactation.
– Adults and children weighing up to 34 kg (for this dosage form)
Use during pregnancy and lactation
Contraindicated.
Composition
1 capsule contains:
Active ingredient: ursodeoxycholic acid 250 mg.
Excipients: lactulose, microcrystalline cellulose, low molecular weight povidone, magnesium stearate, talc.
Hard gelatin capsules: gelatin, titanium dioxide, dye azorubine.
Dosage and administration
The drug is administered orally.
When dissolving cholesterol gallstones, the capsules are taken in the evening, before bedtime, without chewing and drinking a small amount of liquid.
Dose 10 mg / kg body weight daily, which corresponds to: 2 capsules of the drug Ursoliv in patients with body weight up to 60 kg 3 capsules – in patients with body weight up to 80 kg 4 capsules – in patients with body weight up to 100 kg 5 capsules – in patients with body weight over 100 kg. The duration of treatment is 6-12 months.
To prevent re-formation of stones, it is recommended that you take the drug for a few more months after the stones dissolve.
In the symptomatic treatment of primary biliary cirrhosis, the daily dose depends on body weight and ranges from 2 to 6 capsules (10 to 15 mg / kg body weight).
The drug is taken with food, washed down with enough water.
For the treatment of biliary reflux gastritis, 1 capsule is prescribed 1 time / day before bedtime. The course of treatment is from 10-14 days to 6 months, if necessary – up to 2 years.
Side effects
Allergic reactions.
Drug Interaction
When used together, aluminum-containing antacids and ion-exchange resins (cholestyramine) reduce the absorption of UDCA.
When used concomitantly, lipid-lowering drugs (especially clofibrate), estrogens, neomycin, or progestogens (oral contraceptives) increase the saturation of bile with cholesterol and may reduce the ability of ursodeoxycholic acid to dissolve cholesterol.
When used at the same time, UDCA can increase cyclosporine absorption.
Storage conditions
Keep dry, protected from light at a temperature not exceeding 25oC.
Shelf life
4 years.
Deystvuyushtee substance
Ursodezoksiholevaya Chisloth
Terms and conditions
prescription
dosage form
capsule
Possible product names
URSOLIV 0.25 N50 CAPS
Ursoliv 250mg Caps. X50 (R)
Ursoliv caps. 250mg N50 Russia
URSOLIV KAPS. 250MG No. 50
Ursoliv capsules 250 mg 50 pcs.
ABBA RUS, Russia
